Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to email@example.com.
Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 “VIOLET Studies” for Oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC)
Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole for the Treatment of Acute Vulvovaginal Candidiasis
Mycovia Pharmaceuticals CEO Patrick Jordan Named 2020 Life Sciences CEO of the Year by Triangle Business Journal